Literature DB >> 26289631

Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma.

Atsushi Osoegawa1, Takuro Kometani, Seiichi Fukuyama, Fumihiko Hirai, Takashi Seto, Kenji Sugio, Yukito Ichinose.   

Abstract

PURPOSE: As chemotherapy has improved, the survival of patients with metastatic colorectal carcinoma has reached up to 2.5 years. Many of these patients experience pulmonary metastases; however, the prognosis after pulmonary metastasectomy is not satisfying. In this study, we analyzed the prognostic factors for survival in patients who underwent pulmonary metastasectomy.
METHODS: Eighty-seven patients with colorectal carcinoma received pulmonary metastasectomy. The pathological status of the primary tumor, outcome of the pulmonary metastasectomy, disease-free interval, perioperative carcinoembryonic antigen (CEA) level and history of liver metastases were assessed.
RESULTS: The five-year survival was 42.5% after pulmonary metastasectomy. A univariate analyses revealed that the CEA level (p = 0.043) and the number of pulmonary metastases (p = 0.047) were prognostic factors for survival. The CEA level was an independent prognostic factor in a multivariate analysis (relative risk = 2.01, p = 0.037). Among cases with elevated preoperative CEA levels, those whose CEA level normalized after metastasectomy had a better prognosis compared with those whose CEA level decreased but was still high, or whose level increased after metastasectomy (median survival time of 41.8 months compared with 28.1 or 15.7 months, respectively p = 0.021).
CONCLUSION: The CEA level can be a predictive marker for the prognosis in patients with pulmonary metastases from colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26289631      PMCID: PMC4981774          DOI: 10.5761/atcs.oa.14-00345

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  32 in total

1.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Colorectal lung metastases: results of surgical excision.

Authors:  M K McAfee; M S Allen; V F Trastek; D M Ilstrup; C Deschamps; P C Pairolero
Journal:  Ann Thorac Surg       Date:  1992-05       Impact factor: 4.330

3.  Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment.

Authors:  Yukihito Saito; Hideyasu Omiya; Keijiro Kohno; Takanobu Kobayashi; Kazumi Itoi; Masami Teramachi; Masato Sasaki; Hitoyuki Suzuki; Hitoji Takao; Masaharu Nakade
Journal:  J Thorac Cardiovasc Surg       Date:  2002-11       Impact factor: 5.209

4.  Therapeutic video-assisted thoracoscopic surgical resection of colorectal pulmonary metastases.

Authors:  R J Landreneau; T De Giacomo; M J Mack; S R Hazelrigg; P F Ferson; R J Keenan; J D Luketich; A P Yim; G F Coloni
Journal:  Eur J Cardiothorac Surg       Date:  2000-12       Impact factor: 4.191

5.  Surgery for pulmonary metastases from colorectal carcinoma.

Authors:  M Inoue; Y Kotake; K Nakagawa; K Fujiwara; K Fukuhara; T Yasumitsu
Journal:  Ann Thorac Surg       Date:  2000-08       Impact factor: 4.330

6.  Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis.

Authors:  Tomohiko Iida; Hiroaki Nomori; Mitsutoshi Shiba; Jun Nakajima; Sakae Okumura; Hirotoshi Horio; Haruhisa Matsuguma; Norihiko Ikeda; Ichiro Yoshino; Yuichi Ozeki; Keigo Takagi; Tomoyuki Goya; Masafumi Kawamura; Chikuma Hamada; Koichi Kobayashi
Journal:  Ann Surg       Date:  2013-06       Impact factor: 12.969

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Authors:  Howard S Hochster; Lowell L Hart; Ramesh K Ramanathan; Barrett H Childs; John D Hainsworth; Allen L Cohn; Lucas Wong; Louis Fehrenbacher; Yousif Abubakr; M Wasif Saif; Lee Schwartzberg; Eric Hedrick
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

10.  TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

Authors:  Takayuki Yoshino; Nobuyuki Mizunuma; Kentaro Yamazaki; Tomohiro Nishina; Yoshito Komatsu; Hideo Baba; Akihito Tsuji; Kensei Yamaguchi; Kei Muro; Naotoshi Sugimoto; Yasushi Tsuji; Toshikazu Moriwaki; Taito Esaki; Chikuma Hamada; Takanori Tanase; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2012-08-28       Impact factor: 41.316

View more
  5 in total

1.  High Yield of Chest X-ray in the Follow-Up of Colorectal Cancer.

Authors:  Eline G M Steenhuis; Ivonne J H Schoenaker; Jan Willem B De Groot; Jos A Stigt; Onne Reerink; Wouter H De Vos Tot Nederveen Cappel; Henderik L Van Westreenen; Richard M Brohet
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

2.  Pulmonary laser-assisted metastasectomy is associated with prolonged survival in patients with colorectal cancer.

Authors:  Isabelle Moneke; Friederike Funcke; Severin Schmid; Thomas Osei-Agyemang; Bernward Passlick
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

3.  Surgical resection of pulmonary metastases from colorectal cancer: 11 years of experiences.

Authors:  Guoquan Cao; Dezhi Cheng; Lechi Ye; Yiyuan Pan; Fan Yang; Shixu Lyu
Journal:  PLoS One       Date:  2017-04-10       Impact factor: 3.240

Review 4.  Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer.

Authors:  Jakob Nikolas Kather; Niels Halama
Journal:  Br J Cancer       Date:  2019-04-02       Impact factor: 7.640

5.  The Validity of a New Edition of Classification for Ovarian Metastasis from Colorectal Cancer.

Authors:  Terukazu Yoshihara; Shingo Noura; Tsukasa Tanida; Takayuki Ogino; Kozo Noguchi; Hirotsugu Nagase; Masashi Hirota; Yoshito Tomimaru; Hiroshi Imamura; Keizo Dono
Journal:  J Anus Rectum Colon       Date:  2021-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.